-
1
-
-
8244234470
-
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group
-
Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336(23):1641-1648.
-
(1997)
N Engl J Med
, vol.336
, Issue.23
, pp. 1641-1648
-
-
Kaplan, L.D.1
Straus, D.J.2
Testa, M.A.3
-
2
-
-
34547229388
-
Effect of individual HAART treatment on Hodgkin and non-Hodgkin lymphoma risk among HIV patients
-
Dal Maso L, Clifford G, Polesel J, Franceschi S, Rickenbach M. Effect of individual HAART treatment on Hodgkin and non-Hodgkin lymphoma risk among HIV patients. Ann Oncol. 2005;16(Suppl 5):v28a.
-
(2005)
Ann Oncol
, vol.16
, Issue.SUPPL. 5
-
-
Dal Maso, L.1
Clifford, G.2
Polesel, J.3
Franceschi, S.4
Rickenbach, M.5
-
3
-
-
0036500980
-
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia
-
Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002;94(5):1492-1499.
-
(2002)
Cancer
, vol.94
, Issue.5
, pp. 1492-1499
-
-
Cortes, J.1
Thomas, D.2
Rios, A.3
-
4
-
-
0035895086
-
Autologous stem cell transplantation for HIV-associated lymphoma
-
Krishnan A, Molina A, Zaia J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood. 2001;98(13):3857-3859.
-
(2001)
Blood
, vol.98
, Issue.13
, pp. 3857-3859
-
-
Krishnan, A.1
Molina, A.2
Zaia, J.3
-
5
-
-
22344450861
-
AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy
-
Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23(19):4430-4438.
-
(2005)
J Clin Oncol
, vol.23
, Issue.19
, pp. 4430-4438
-
-
Lim, S.T.1
Karim, R.2
Nathwani, B.N.3
Tulpule, A.4
Espina, B.5
Levine, A.M.6
-
6
-
-
85112378864
-
HIV-related lymphoma: Changes in immune parameters and viral load during chemotherapy
-
Weiss R, Mitrou P, Arasteh K, Schurmann D, Huhn D. HIV-related lymphoma: changes in immune parameters and viral load during chemotherapy. Blood. 2000;96(11):134a.
-
(2000)
Blood
, vol.96
, Issue.11
-
-
Weiss, R.1
Mitrou, P.2
Arasteh, K.3
Schurmann, D.4
Huhn, D.5
-
7
-
-
0035902947
-
Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy
-
Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS. 2001;15(12):1483-1491.
-
(2001)
AIDS
, vol.15
, Issue.12
, pp. 1483-1491
-
-
Antinori, A.1
Cingolani, A.2
Alba, L.3
-
8
-
-
0035889139
-
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy
-
Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98(8):2339-2344.
-
(2001)
Blood
, vol.98
, Issue.8
, pp. 2339-2344
-
-
Besson, C.1
Goubar, A.2
Gabarre, J.3
-
9
-
-
0035072134
-
Changing incidence and survival in patients with AIDS-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART)
-
Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, Brodt HR. Changing incidence and survival in patients with AIDS-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leukemia Lymphoma. 2001;41(1 -2):105-116.
-
(2001)
Leukemia Lymphoma
, vol.41
, Issue.1 -2
, pp. 105-116
-
-
Chow, K.U.1
Mitrou, P.S.2
Geduldig, K.3
Helm, E.B.4
Hoelzer, D.5
Brodt, H.R.6
-
10
-
-
0035760292
-
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy [comment]
-
Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy [comment]. Blood. 2001;98(12):3406-3412.
-
(2001)
Blood
, vol.98
, Issue.12
, pp. 3406-3412
-
-
Kirk, O.1
Pedersen, C.2
Cozzi-Lepri, A.3
-
11
-
-
0034667530
-
Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy
-
Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96(8):2730-2734.
-
(2000)
Blood
, vol.96
, Issue.8
, pp. 2730-2734
-
-
Matthews, G.V.1
Bower, M.2
Mandalia, S.3
Powles, T.4
Nelson, M.R.5
Gazzard, B.G.6
-
12
-
-
0037342949
-
Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy
-
Navarro JT, Ribera JM, Oriol A, Tural C, Milla F, Feliu E. Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;32(3):347-348.
-
(2003)
J Acquir Immune Defic Syndr
, vol.32
, Issue.3
, pp. 347-348
-
-
Navarro, J.T.1
Ribera, J.M.2
Oriol, A.3
Tural, C.4
Milla, F.5
Feliu, E.6
-
13
-
-
0005376590
-
Highly active antiretroviral therapy (HAART) significantly improves disease free survival (DFS) in patients (pts) with HIV-related non-Hodgkin's lymphoma (HIV-NHL) treated with chemotherapy (CT)
-
Vaccher E, di Gennaro G, Shioppa O, et al. Highly active antiretroviral therapy (HAART) significantly improves disease free survival (DFS) in patients (pts) with HIV-related non-Hodgkin's lymphoma (HIV-NHL) treated with chemotherapy (CT). Proc ASCO. 2001;20(2):294a.
-
(2001)
Proc ASCO
, vol.20
, Issue.2
-
-
Vaccher, E.1
di Gennaro, G.2
Shioppa, O.3
-
14
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
-
(2002)
N Engl J Med
, vol.346
, Issue.4
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
-
15
-
-
24644500086
-
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
-
Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033.
-
(2005)
J Clin Oncol
, vol.23
, Issue.22
, pp. 5027-5033
-
-
Sehn, L.H.1
Donaldson, J.2
Chhanabhai, M.3
-
16
-
-
23944508056
-
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010
-
Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538-1543.
-
(2005)
Blood
, vol.106
, Issue.5
, pp. 1538-1543
-
-
Kaplan, L.D.1
Lee, J.Y.2
Ambinder, R.F.3
-
17
-
-
2342635848
-
Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group Trial (E1494)
-
Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol. 2004;22(8):1491-1500.
-
(2004)
J Clin Oncol
, vol.22
, Issue.8
, pp. 1491-1500
-
-
Sparano, J.A.1
Lee, S.2
Chen, M.G.3
-
18
-
-
20144367599
-
Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: Pooled results from 3 phase 2 trials
-
Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105(5):1891-1897.
-
(2005)
Blood
, vol.105
, Issue.5
, pp. 1891-1897
-
-
Spina, M.1
Jaeger, U.2
Sparano, J.A.3
-
19
-
-
0035397512
-
Human immunodeficiency virus-related non-Hodgkin lymphoma: Activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients
-
Spina M, Vaccher E, Juzbasic S, et al. Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer. 2001;92(1):200-206.
-
(2001)
Cancer
, vol.92
, Issue.1
, pp. 200-206
-
-
Spina, M.1
Vaccher, E.2
Juzbasic, S.3
-
20
-
-
0000717261
-
Diffuse large B-cell lymphoma
-
Jaffe ES, Harris NL, Stein H, Vardiman JW, eds, Lyon, PA: IARC Press;
-
Gatter KC, Warmke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, PA: IARC Press; 2001:171-174.
-
(2001)
World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues
, pp. 171-174
-
-
Gatter, K.C.1
Warmke, R.A.2
-
21
-
-
0030666522
-
Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: Natural history of relapse after initial complete response and prognostic variables defining outcome after relapse
-
Hoskins PJ, Le N, Gascoyne RD, et al. Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapse. Ann Oncol. 1997;8(11):1125-1132.
-
(1997)
Ann Oncol
, vol.8
, Issue.11
, pp. 1125-1132
-
-
Hoskins, P.J.1
Le, N.2
Gascoyne, R.D.3
-
22
-
-
0026097554
-
MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease
-
O'Reilly SE, Hoskins P, Klimo P, Connors JM. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol. 1991;2(Suppl 1):17-23.
-
(1991)
Ann Oncol
, vol.2
, Issue.SUPPL. 1
, pp. 17-23
-
-
O'Reilly, S.E.1
Hoskins, P.2
Klimo, P.3
Connors, J.M.4
-
23
-
-
0345334246
-
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA
-
Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996;276(2):146-154.
-
(1996)
JAMA
, vol.276
, Issue.2
, pp. 146-154
-
-
Carpenter, C.C.1
Fischl, M.A.2
Hammer, S.M.3
-
24
-
-
0033458716
-
The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma
-
Rossi G, Donisi A, Casari S, Re A, Cadeo G, Carosi G. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer. 1999;86(11):2391-2397.
-
(1999)
Cancer
, vol.86
, Issue.11
, pp. 2391-2397
-
-
Rossi, G.1
Donisi, A.2
Casari, S.3
Re, A.4
Cadeo, G.5
Carosi, G.6
-
25
-
-
23644432624
-
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy
-
Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med. 2005;143(4):265-273.
-
(2005)
Ann Intern Med
, vol.143
, Issue.4
, pp. 265-273
-
-
Bower, M.1
Gazzard, B.2
Mandalia, S.3
-
26
-
-
4344613254
-
No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: Updated data from AIDS malignancies consortium study 010
-
Kaplan LD, Lee J, Scadden DT. No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: updated data from AIDS malignancies consortium study 010. Blood. 2003;102(11):409-410a.
-
(2003)
Blood
, vol.102
, Issue.11
-
-
Kaplan, L.D.1
Lee, J.2
Scadden, D.T.3
-
27
-
-
0027394689
-
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
-
Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002-1006.
-
(1993)
N Engl J Med
, vol.328
, Issue.14
, pp. 1002-1006
-
-
Fisher, R.I.1
Gaynor, E.R.2
Dahlberg, S.3
-
28
-
-
9044226138
-
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen
-
Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14(3):925-934.
-
(1996)
J Clin Oncol
, vol.14
, Issue.3
, pp. 925-934
-
-
Magrath, I.1
Adde, M.2
Shad, A.3
-
29
-
-
33748657979
-
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma
-
Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(25):4123-4128.
-
(2006)
J Clin Oncol
, vol.24
, Issue.25
, pp. 4123-4128
-
-
Boue, F.1
Gabarre, J.2
Gisselbrecht, C.3
-
30
-
-
13644249821
-
Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update
-
Habermann TM, Weller E, Morrison VA, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood. 2004;104(11):40a.
-
(2004)
Blood
, vol.104
, Issue.11
-
-
Habermann, T.M.1
Weller, E.2
Morrison, V.A.3
-
31
-
-
33645504592
-
The case for rituximab in AIDS-related lymphoma
-
Dunleavy K, Wilson WH, Kaplan LD. The case for rituximab in AIDS-related lymphoma. Blood. 2006;107(7):3014-3015.
-
(2006)
Blood
, vol.107
, Issue.7
, pp. 3014-3015
-
-
Dunleavy, K.1
Wilson, W.H.2
Kaplan, L.D.3
-
32
-
-
0033572954
-
AIDS-related opportunistic illnesses occurring after initiation of potent anti-retroviral therapy: The Swiss HIV Cohort Study [comment]
-
Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent anti-retroviral therapy: the Swiss HIV Cohort Study [comment]. JAMA. 1999;282(23):2220-2226.
-
(1999)
JAMA
, vol.282
, Issue.23
, pp. 2220-2226
-
-
Ledergerber, B.1
Egger, M.2
Erard, V.3
-
33
-
-
0030727417
-
Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient
-
Weir A, Wansbrough-Jones M. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS. 1997;11(15):1895- 1896.
-
(1997)
AIDS
, vol.11
, Issue.15
, pp. 1895-1896
-
-
Weir, A.1
Wansbrough-Jones, M.2
-
34
-
-
0037930774
-
Delayed-onset neutropenia associated with rituximab therapy
-
Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003;121(6):913-918.
-
(2003)
Br J Haematol
, vol.121
, Issue.6
, pp. 913-918
-
-
Chaiwatanatorn, K.1
Lee, N.2
Grigg, A.3
Filshie, R.4
Firkin, F.5
-
35
-
-
23244448555
-
Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: Case report and literature review
-
Motl SE, Baskin RC. Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review. Pharmacotherapy. 2005;25(8):1151-1155.
-
(2005)
Pharmacotherapy
, vol.25
, Issue.8
, pp. 1151-1155
-
-
Motl, S.E.1
Baskin, R.C.2
|